Selective histone deacetylase inhibitors with anticancer activity

Current Topics in Medicinal Chemistry

Volumn 16, Issue 4, 2016, Pages 415-426

  Ma, Nan ^a,b,c   Luo, Ying ^d   Wang, Ying ^b   Liao, Chenzhong ^d   Ye, Wen Cai ^b,c   Jiang, Sheng ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b JINAN UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

^d HEFEI UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Class I; Class II; Class III; HDAC; HDAC1; HDAC6; Selective histone deacetylase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; APICIDIN; AZUMAMIDE B; AZUMAMIDE C; AZUMAMIDE E; BELINOSTAT; CHLAMYDOCIN; CYCLIC HYDROXAMIC ACID CONTAINING PEPTIDE; CYCLOPEPTIDE; DEPSIPEPTIDE; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; LARGAZOLE; PANOBINOSTAT; ROMIDEPSIN; SIRTUIN; SPIRUCHOSTATIN A; SPIRUCHOSTATIN B; TETRAPEPTIDE; THAILANDEPSIN; TRAPOXIN A; TRAPOXIN B; TRIAZOLE DERIVATIVE; TRICHOSTATIN A; TRICHOSTATIN A DERIVATIVE; TUBACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKHOLDERIA THAILANDENSIS; CHEMICAL MODIFICATION; CHROMOBACTERIUM VIOLACEUM; CLINICAL TRIAL (TOPIC); DRUG SELECTIVITY; DRUG TARGETING; HUMAN; IC50; MOLECULAR DOCKING; NEOPLASM; NONHUMAN; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84979098356     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150813145629     Document Type: Article

References (74)

1. Roth, S.Y., Denu, J.M., Allis, C.D. Histone acetyltransferases. Annu. Rev. Biochem., 2001, 70, 81-120.
2. Thiagalingam, S., Cheng, K.H., Lee, H.J., Mineva, N. Thiagalingam, A., Ponte, J. F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci., 2003, 983, 84-100.
3. Yoshida, M., Kijima, M., Akita, M., Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 1990, 265 (28), 17174-9.
4. Lauffer, B.E., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., Ortwine, D.F., Gunzner, J., Modrusan, Z., Neumann, L., Koth, C.M., Lupardus, P.J., Kaminker, J.S., Heise, C.E., Steiner, P.: Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J. Biol. Chem., 2013, 288 (37), 26926-43.
5. Finnin, M.S., Donigian, J.R., Cohen, A., Richon, V.M., Rifkind, R.A., Marks, P.A., Breslow, R., Pavletich, N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 1999, 401 (6749), 188-193.
6. Miller, T.A., Witter, D.J., Belvedere, S. Histone Deacetylase Inhibitors. J. Med. Chem., 2003, 46 (24), 5097-5116.
7. de Ruijter, A.J., van Gennip, A.H., Caron, H.N., Kemp, S., van Kuilenburg, A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J., 2003, 370 (Pt 3), 737-49.
8. Knoepfler, P.S., Eisenman, R.N., Sin Meets NuRD and Other Tails of Repression. Cell, 1999, 99 (5), 447-450.
9. Wilson, A.J., Byun, D.S., Popova, N., Murray, L.B., L’Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L.H., Mariadason, J.M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem., 2006, 281 (19), 13548-13558.
10. Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., Nakanishi, O., Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem., 1999, 42 (15), 3001-3003.
11. Beckers, T., Burkhardt, C., Wieland, H., Gimmnich, P., Ciossek, T., Maier, T., Sanders, K. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer, 2007, 121 (5), 1138-1148.
12. Hu, E., Dul, E., Sung, C.M., Chen, Z., Kirkpatrick, R., Zhang, G.F., Johanson, K., Liu, R., Lago, A., Hofmann, G., Macarron, R., de los Frailes, M., Perez, P., Krawiec, J., Winkler, J., Jaye, M., Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther., 2003, 307 (2), 720-728.
13. Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S.C., Carey, N., Finn, P.W., Collins, L.S., Tumber, A., Ritchie, J.W., Jensen, P.B., Lichenstein, H.S., Sehested, M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J., 2008, 409 (2), 581-589.
14. Moradei, O.M., Mallais, T.C., Frechette, S., Paquin, I., Tessier, P.E., Leit, S.M., Fournel, M., Bonfils, C., Trachy-Bourget, M.C., Liu, J., Yan, T.P., Lu, A.H., Rahil, J., Wang, J., Lefebvre, S., Li, Z., Vaisburg, A.F., Besterman, J.M. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J. Med. Chem., 2007, 50 (23), 5543-5546.
15. Witter, D.J., Harrington, P., Wilson, K.J., Chenard, M., Fleming, J.C., Haines, B., Kral, A.M., Secrist, J.P., Miller, T.A. Optimization of biaryl Selective HDAC1& 2 Inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett., 2008, 18 (2), 726-731.
16. Methot, J.L., Chakravarty, P.K., Chenard, M., Close, J., Cruz, J.C., Dahlberg, W.K., Fleming, J., Hamblett, C.L., Hamill, J.E., Harrington, P., Harsch, A., Heidebrecht, R., Hughes, B., Jung, J., Kenific, C.M., Kral, A.M., Meinke, P.T., Middleton, R.E., Ozerova, N., Sloman, D.L., Stanton, M.G., Szewczak, A.A., Tyagarajan, S., Witter, D.J., Secrist, J.P., Miller, T.A. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett., 2008, 18 (3), 973-978.
17. Wilson, K.J., Witter, D.J., Grimm, J.B., Siliphaivanh, P., Otte, K.M., Kral, A.M., Fleming, J.C., Harsch, A., Hamill, J.E., Cruz, J.C., Chenard, M., Szewczak, A.A., Middleton, R.E., Hughes, B.L., Dahlberg, W.K., Secrist, J.P., Miller, T.A. Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1). Bioorg. Med. Chem. Lett., 2008, 18 (6), 1859-1863.
18. Methot, J.L., Hamblett, C.L., Mampreian, D.M., Jung, J., Harsch, A., Szewczak, A.A., Dahlberg, W.K., Middleton, R.E., Hughes, B., Fleming, J.C., Wang, H., Kral, A.M., Ozerova, N., Cruz, J.C., Haines, B., Chenard, M., Kenific, C.M., Secrist, J.P., Miller, T.A. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett., 2008, 18 (23), 6104-6109.
19. Furumai, R., Matsuyama, A., Kobashi, N., Lee, K.H., Nishiyama, M., Nakajima, H., Tanaka, A., Komatsu, Y., Nishino, N., Yoshida, M., Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res., 2002, 62 (17), 4916-4921.
20. Yurek-George, A., Cecil, A.R., Mo, A.H., Wen, S., Rogers, H., Habens, F., Maeda, S., Yoshida, M., Packham, G., Ganesan, A. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor. J. Med. Chem., 2007, 50(23), 5720-5726.
21. Taori, K., Paul, V.J., Luesch, H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J. Am. Chem. Soc., 2008, 130 (6), 1806-1807.
22. Li, S., Yao, H., Xu, J., Jiang, S. Synthetic routes and biological evaluation of largazole and its analogues as potent histone deacetylase inhibitors. Molecules, 2011, 16 (6), 4681-4694.
23. Bhansali, P., Hanigan, C.L., Casero, R.A., Tillekeratne, L.M., Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation. J. Med. Chem., 2011, 54 (21), 7453-7463.
24. Ying, Y., Liu, Y., Byeon, S. R., Kim, H., Luesch, H., Hong, J. Synthesis and activity of largazole analogues with linker and macrocycle modification. Org. Lett., 2008, 10 (18), 4021-4024.
25. Li, X., Tu, Z., Li, H., Liu, C., Li, Z., Sun, Q., Yao, Y., Liu, J., Jiang, S. Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry. ACS Med. Chem. Lett., 2013, 4 (1), 132-136.
26. Zeng, X., Yin, B., Hu, Z., Liao, C., Li, Z., Zhou, G., Jiang, S. Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells. Org. Lett., 2010, 12, 1368-1371.
27. Cole, K.E., Dowling, D.P., Boone, M.A., Phillips, A.J., Christianson, D.W. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J. Am. Chem. Soc., 2011, 133 (32), 12474-12477.
28. Yurek-George, A., Habens, F., Brimmell, M., Packham, G., Ganesan, A. Total synthesis of spiruchostatin A, a potent histone deacetylase inhibitor. J. Am. Chem. Soc., 2004, 126 (4), 1030-1031.
29. Kanno, S., Maeda, N., Tomizawa, A., Yomogida, S., Katoh, T., Ishikawa, M. Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells. Int. J. Oncol., 2012, 40 (5), 1391-1396.
30. Klausmeyer, P., Shipley, S.M., Zuck, K.M., McCloud, T.G. Histone deacetylase inhibitors from Burkholderia thailandensis. J. Nat. Prod., 2011, 74 (10), 2039-2044.
31. Wang, C., Henkes, L.M., Doughty, L.B., He, M., Wang, D., Meyer-Almes, F.J., Cheng, Y.Q. Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broadspectrum antiproliferative activities. J. Nat. Prod., 2011, 74 (10), 2031-2038.
32. Biggins, J.B., Gleber, C.D., Brady, S.F. Acyldepsipeptide HDAC inhibitor production induced in Burkholderia thailandensis. Org. Lett., 2011, 13 (6), 1536-1539.
33. Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA, 2001, 98 (1), 87-92.
34. Hildmann, C., Wegener, D., Riester, D., Hempel, R., Schober, A., Merana, J., Giurato, L., Guccione, S., Nielsen, T. K., Ficner, R., Schwienhorst, A., Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J. Biotechnol., 2006, 124 (1), 258-270.
35. Closse, A., Huguenin, R. Isolation and structural clarification of chlamydocin. Helv Chim Acta, 1974, 57 (3), 533-545.
36. Bhuiyan, M. P., Kato, T., Okauchi, T., Nishino, N., Maeda, S., Nishino, T. G., Yoshida, M. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg. Med. Chem., 2006, 14 (10), 3438-3446.
37. Islam, M.S., Bhuiyan, M.P., Islam, M.N., Nsiama, T.K., Oishi, N., Kato, T., Nishino, N., Ito, A., Yoshida, M. Evaluation of functional groups on amino acids in cyclic tetrapeptides in histone deacetylase inhibition. Amino Acids, 2012, 42 (6), 2103-2110.
38. Heltweg, B., Dequiedt, F., Marshall, B.L., Brauch, C., Yoshida, M., Nishino, N., Verdin, E., Jung, M. Subtype selective substrates for histone deacetylases. J. Med. Chem., 2004, 47 (21), 5235-5243.
39. Colletti, S.L., Myers, R.W., Darkin-Rattray, S.J., Gurnett, A.M., Dulski, P.M., Galuska, S., Allocco, J.J., Ayer, M.B., Li, C., Lim, J., Crumley, T.M., Cannova, C., Schmatz, D.M., Wyvratt, M.J., Fisher, M.H., Meinke, P.T. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1. Bioorg. Med. Chem. Lett., 2001, 11 (2), 107-111.
40. Singh, S.B., Zink, D.L., Liesch, J.M., Mosley, R.T., Dombrowski, A.W., Bills, G.F., Darkin-Rattray, S.J., Schmatz, D.M., Goetz, M.A. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal alpha-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J. Org. Chem., 2002, 67 (3), 815-825.
41. Nakao, Y., Yoshida, S., Matsunaga, S., Shindoh, N., Terada, Y., Nagai, K., Yamashita, J.K., Ganesan, A., van Soest, R.W., Fusetani, N. Azumamides A-E: Histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis. Angew. Chem. Int. Ed. Engl., 2006, 45 (45), 7553-7557.
42. Nakao, Y., Narazaki, G., Hoshino, T., Maeda, S., Yoshida, M., Maejima, H., Yamashita, J.K. Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg. Med. Chem. Lett., 2008, 18 (9), 2982-2984.
43. Jones, P., Altamura, S., Chakravarty, P.K., Cecchetti, O., De Francesco, R., Gallinari, P., Ingenito, R., Meinke, P.T., Petrocchi, A., Rowley, M., Scarpelli, R., Serafini, S., Steinkuhler, C. A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16 (23), 5948-5952.
44. Shinji, C., Maeda, S., Imai, K., Yoshida, M., Hashimoto, Y., Miyachi, H. Design, synthesis, and evaluation of cyclic amide/imidebearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem., 2006, 14 (22), 7625-7651.
45. Siliphaivanh, P., Harrington, P., Witter, D.J., Otte, K., Tempest, P., Kattar, S., Kral, A.M., Fleming, J.C., Deshmukh, S.V., Harsch, A., Secrist, P.J., Miller, T.A. Design of novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17 (16), 4619-4624.
46. Hamblett, C.L., Methot, J.L., Mampreian, D.M., Sloman, D.L., Stanton, M.G., Kral, A.M., Fleming, J.C., Cruz, J.C., Chenard, M., Ozerova, N., Hitz, A.M., Wang, H., Deshmukh, S.V., Nazef, N., Harsch, A., Hughes, B., Dahlberg, W.K., Szewczak, A.A., Middleton, R.E., Mosley, R.T., Secrist, J.P., Miller, T.A. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17 (19), 5300-5309.
47. Sun, Q., Yao, Y., Liu, C., Li, H., Yao, H., Xue, X., Liu, J., Tu, Z., Jiang, S. Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry. Bioorg. Med. Chem. Lett., 2013, 23 (11), 3295-3299.
48. Shen, J., Woodward, R., Kedenburg, J.P., Liu, X., Chen, M., Fang, L., Sun, D., Wang, P.G. Histone deacetylase inhibitors through click chemistry. J. Med. Chem., 2008, 51 (23), 7417-7427.
49. Canzoneri, J.C., Chen, P.C., Oyelere, A.K. Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide. Bioorg. Med. Chem. Lett., 2009, 19 (23), 6588-6590.
50. Park, J.H., Jung, Y., Kim, T.Y., Kim, S.G., Jong, H.S., Lee, J.W., Kim, D.K., Lee, J.S., Kim, N.K., Kim, T.Y., Bang, Y.J. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res., 2004, 10 (15), 5271-5281.
51. Somoza, J.R., Skene, R.J., Katz, B.A., Mol, C., Ho, J.D., Jennings, A.J., Luong, C., Arvai, A., Buggy, J.J., Chi, E., Tang, J., Sang, B.C., Verner, E., Wynands, R., Leahy, E.M., Dougan, D.R., Snell, G., Navre, M., Knuth, M.W., Swanson, R.V., McRee, D.E., Tari, L.W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure, 2004, 12 (7), 1325-1334.
52. Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., Buggy, J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 2008, 22 (5), 1026-1034.
53. Suzuki, T., Ota, Y., Ri, M., Bando, M., Gotoh, A., Itoh, Y., Tsumoto, H., Tatum, P.R., Mizukami, T., Nakagawa, H., Iida, S., Ueda, R., Shirahige, K., Miyata, N.: Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. J. Med. Chem., 2012, 55 (22), 9562-9575.
54. Suzuki, T., Muto, N., Bando, M., Itoh, Y., Masaki, A., Ri, M., Ota, Y., Nakagawa, H., Iida, S., Shirahige, K., Miyata, N. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors. ChemMedChem, 2014, 9 (3), 657-664.
55. Li, X., Inks, E.S., Li, X., Hou, J., Chou, C.J., Zhang, J., Jiang, Y., Zhang, Y., Xu, W. Discovery of the first N-hydroxycinnamamidebased histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity. J. Med. Chem., 2014, 57 (8), 3324-3341.
56. Gallinari, P., Di Marco, S., Jones, P., Pallaoro, M., Steinkuhler, C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res., 2007, 17 (3), 195-211.
57. Verdin, E., Dequiedt, F., Kasler, H.G. Class II histone deacetylases: versatile regulators. Trends Genet., 2003, 19 (5), 286-293.
58. Haggarty, S.J., Koeller, K.M., Wong, J.C., Grozinger, C.M., Schreiber, S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA, 2003, 100 (8), 4389-4394.
59. Zou, H., Wu, Y., Navre, M., Sang, B.C. Characterization of the two catalytic domains in histone deacetylase 6. Biochem. Biophys. Res. Commun., 2006, 341 (1), 45-50.
60. Kozikowski, A.P., Chen, Y., Gaysin, A.M., Savoy, D.N., Billadeau, D.D., Kim, K.H. Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem, 2008, 3 (3), 487-501.
61. Chen, Y., Lopez-Sanchez, M., Savoy, D.N., Billadeau, D.D., Dow, G.S., Kozikowski, A.P. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J. Med. Chem., 2008, 51 (12), 3437-3448.
62. Schafer, S., Saunders, L., Eliseeva, E., Velena, A., Jung, M., Schwienhorst, A., Strasser, A., Dickmanns, A., Ficner, R., Schlimme, S., Sippl, W., Verdin, E., Jung, M. Phenylalaninecontaining hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg. Med. Chem., 2008, 16 (4), 2011-2033.
63. Duan, W., Li, J., Inks, E.S., Chou, C.J., Jia, Y., Chu, X., Li, X., Xu, W., Zhang, Y. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor. J. Med. Chem., 2015, 58 (10), 4325-4338.
64. Yao, Y., Liao, C., Li, Z., Wang, Z., Sun, Q., Liu, C., Yang, Y., Tu, Z., Jiang, S. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. Eur. J. Med. Chem, 2014, 86, 639-652.
65. Kong, Y., Jung, M., Wang, K., Grindrod, S., Velena, A., Lee, S. A., Dakshanamurthy, S., Yang, Y., Miessau, M., Zheng, C., Dritschilo, A., Brown, M. L., Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Mol. Cancer Ther., 2011, 10 (9), 1591-1599.
66. Bergman, J.A., Woan, K., Perez-Villarroel, P., Villagra, A., Sotomayor, E.M., Kozikowski, A.P. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J. Med. Chem., 2012, 55 (22), 9891-9899.
67. Kozikowski, A.P., Chen, Y., Gaysin, A., Chen, B., D’Annibale, M.A., Suto, C.M., Langley, B.C. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J. Med. Chem., 2007, 50 (13), 3054-3061.
68. Du, H., Guo, L., Yan, S., Sosunov, A.A., McKhann, G.M., Yan, S.S. Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. Proc. Natl. Acad. Sci. USA, 2010, 107 (43), 18670-18675.
69. Suzuki, T., Kouketsu, A., Itoh, Y., Hisakawa, S., Maeda, S., Yoshida, M., Nakagawa, H., Miyata, N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a smallmolecular substrate. J. Med. Chem., 2006, 49 (16), 4809-4812.
70. Itoh, Y., Suzuki, T., Kouketsu, A., Suzuki, N., Maeda, S., Yoshida, M., Nakagawa, H., Miyata, N. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J. Med. Chem., 2007, 50 (22), 5425-5438.
71. Jones, P., Bottomley, M.J., Carfi, A., Cecchetti, O., Ferrigno, F., Lo Surdo, P., Ontoria, J.M., Rowley, M., Scarpelli, R., Schultz-Fademrecht, C., Steinkuhler, C. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18 (11), 3456-3461.
72. Patil, V., Sodji, Q.H., Kornacki, J.R., Mrksich, M., Oyelere, A.K. 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition. J. Med. Chem., 2013, 56 (9), 3492-3506.
73. Trapp, J., Jochum, A., Meier, R., Saunders, L., Marshall, B., Kunick, C., Verdin, E., Goekjian, P., Sippl, W., Jung, M. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Med. Chem., 2006, 49 (25), 7307-7316.
74. Tervo, A.J., Kyrylenko, S., Niskanen, P., Salminen, A., Leppanen, J., Nyronen, T.H., Jarvinen, T., Poso, A. An in silico approach to discovering novel inhibitors of human sirtuin type 2. J. Med. Chem., 2004, 47 (25), 6292-6298.